|
|
 |
| |
provides pharma-specific market intelligence on Medicaid including current market trends analysis, forward-looking scenarios, profiles of leading managed Medicaid customers, and therapeutic class-specific information.
Research enables pharmaceutical and biotech professionals to:
- Develop more proactive and profitable strategies for securing product access with Medicaid customers
- Improve relationships with managed Medicaid customers
- Improve internal education on Medicaid trends and success factors
 View our 2010 Medicaid Rx Payers research schedule.
View our 2011 Medicaid Rx Payers research schedule.
|
Subscribing Companies Receive
- Customized onsite briefings
- Inquiry privileges—ask the questions you need to put the information to work
- Print copies of research reports & access via a customized website for your company
Contact Medicaid Rx Payers
|
| Medicaid Rx Payers Publications |
2011
Landscape and Evolution of Medicaid - 2011
Coming February 2011
This research provides a comprehensive overview of the current Medicaid marketplace and key trends in pharmacy management. This report will guide pharmaceutical and biotechnology companies to help plan for the skills and resources that will be needed 3-5 years in the future.
Medicaid HMO and PBA Profiles and Assessments - 2011
Coming April 2011
Identifies and evaluates the major player in the very different PBA and managed Medicaid HMO segments; Profiles and assesses the organizations for their importance to manufacturers based on a variety of factors.
State Segmentation and Database - 2011
Coming July 2011
Analyzes state characteristics to develop a segmentation model for identifying opportunities with states. Answers the question: What segmentation approaches are relevant for identifying opportunities for working with state customers?
Managed Medicaid Drug Category Profiles - 2011
Coming October 2011
This report provides profiles of 10 high-volume therapeutic categories which contain information on formulary theory and use, contracting trends, disease management, utilization management and selection criteria, and external influencers, such as technology assessment outfits.
2010
Landscapes and Evolution of Medicaid 2010
February 2010
Landscape report provides situation analysis of the current Medicaid marketplace and key trends. Evolution report features forward-looking research to identify possible scenarios in the evolution of Medicaid, discerning specific implications for pharmaceutical and biotech manufacturers. Medicaid HMO and PBA Profiles and Assessments 2010
April 2010
Identifies and evaluates the major players in the very different PBA and managed Medicaid HMO segments; Profiles and assesses the organizations for their importance to manufacturers based on a variety of factors. State Segmentation and Database
Coming June 2010
This report and database will help clients determine what segmentation approaches are relevant for identifying opportunities for working with state customers.
Managed Medicaid Drug Category Profiles 2010
Coming October 2010
Based on a survey of Medicaid HMO pharmacy and medical directors, this report analyzes needs, value propositions, philosophies and actions of Medicaid HMOs relative to ten specific high-volume therapeutic categories.
2009
Landscapes and Evolution of Medicaid 2009
March 2009
Landscape report provides situation analysis of the current Medicaid marketplace and key trends. Evolution report features forward-looking research to identify possible scenarios in the evolution of Medicaid, discerning specific implications for pharmaceutical and biotech manufacturers. Identifies and evaluates the major players in the very different PBA and managed Medicaid HMO segments; Profiles and assesses the organizations for their importance to manufacturers based on a variety of factors. This report analyzes needs, value propositions, philosophies, and actions of Medicaid HMOs in 12 therapeutic categories: Antidepressants, Antidiabetics, Antihypertensives, Antipsychotics, Antiretrovirals, Asthma, Autoimmune, Human Growth Hormones, Migraine, Neuropathic Pain, Oncologics, and Proton Pump Inhibitors.
|
|
